On Thursday, Shares of Nymox Pharmaceutical Corporation (NASDAQ:NYMX), gained 8.94% to $1.44.
Nymox Pharmaceutical, declared long-term clinical trial results from the Company’s NX-1207 Phase 2 prostate cancer study NX03-0040. The new results demonstrate statistically noteworthy(p=.0067) better outcomes at up to 2.8 years for NX-1207 treated patients contrast to controls. Trial participants comprised of 146 patients with low grade localized prostate cancer at 44 U.S. investigational sites.
A controlled comparison was conducted of patients who required and received radiation and surgery treatments for their cancer based on blinded post-treatment upgraded evaluations of their pre-treatment initially positive lower grade cancers. The study found that after up to 2.8 years for NX-1207 single-injection treated patients there was a 68.2% reduction contrast to controls in the proportion of patients who had upgraded blinded biopsy results in the treated area and went on to require and receive radiation therapy and/or prostatectomy (surgery) (p=.0067). The new study also found that all instances of surgery or radiation, counting elective cases without upgrades, were reduced by 62.7% (p=.0035) in NX-1207 patients contrast to the randomized control group.
Long-term clinical outcome is a highly important measure of drug treatment efficacy. Patients were randomized to one of two doses of NX-1207 (2.5 mg or 15 mg) or to active surveillance (control). The drug was injected into the area of the prostate where the cancer was detected and repeat biopsies, serial PSA measurements and long-term follow-up were performed on all patients treated and controls.
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of products for the aging population. It offers NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products; and AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer’s disease.
Shares of Sangamo Biosciences Inc. (NASDAQ:SGMO), gained 8.14% to $15.54, during its last trading session.
Sangamo BioSciences, stated its first quarter 2015 financial results and accomplishments.
For the first quarter ended March 31, 2015, Sangamo stated a merged net loss of $5.3 million, or $0.08 per share, contrast to a net loss of $7.6 million, or $0.12 per share, for the same period in 2014. As of March 31, 2015, the Company had cash, cash equivalents, marketable securities and interest receivable of $226.1 million.
Revenues for the first quarter of 2015 were $13.5 million, contrast to $8.1 million for the same period in 2014. First quarter 2015 revenues were generated from the Company’s partnership agreements with Shire International GmbH (Shire), Biogen Inc. (Biogen), and Sigma-Aldrich Corporation (Sigma), enabling technology agreements and research grants. The revenues recognized for the first quarter of 2015 comprised of $12.7 million in partnership and enabling technology agreements and $0.8 million in research grants, contrast to $7.6 million and $0.5 million, respectively, for the same period in 2014. The enhance in partnership agreement revenues was primarily due to enhances in revenues under the Company’s partnership agreements with Sigma and Biogen.
In the first quarter of 2015, Sangamo recognized $4.5 million of revenues related to research services performed under the partnership agreement with Shire, and $1.5 million of revenues related to research services performed under the partnership agreement with Biogen. In addition, following the agreements reached with Shire in January 2012 and Biogen in January 2014, Sangamo received upfront payments of $13.0 million and $20.0 million, respectively. These payments are being recognized as revenue on a straight-line basis over the initial six-year research term for Shire and about 40 months for Biogen. The Company recognized $0.5 million of the Shire upfront payment and $1.5 million of the Biogen upfront payment as revenue for the first quarter of 2015.
Research and development expenses were $15.0 million for the first quarter of 2015, contrast to $12.1 million for the same period in 2014. The enhance was primarily due to enhances in manufacturing expenses, external research expenses associated with our preclinical programs, and personnel-related expenses, counting stock-based compensation. General and administrative expenses were $4.7 million for the first quarter of 2015, contrast to $3.6 million for the same period in 2014. The enhance was primarily due to enhances in personnel-related expenses, counting stock-based compensation, in addition to enhances in legal and professional services.
Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of engineered DNA-binding proteins as novel therapeutic products for unmet medical needs in the United States.
At the end of Thursday’s trade, Shares of Dunkin’ Brands Group, Inc. (NASDAQ:DNKN), gained 7.94% to $51.51, hitting its highest level.
S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 indices:
- Dunkin’ Brands, will replace Riverbed Technology Inc. (RVBD) in the S&P MidCap 400 after the close of trading on Monday, April 27. A group led by Thoma Bravo LLC is acquiring Riverbed Technology in a deal predictable to be accomplished tomorrow.
- Walker & Dunlop Inc. (WD) will replace Entropic Communications Inc. (ENTR) in the S&P SmallCap 600 after the close of trading on Thursday, April 30. MaxLinear Inc. (MXL) is acquiring Entropic Communications in a transaction predictable to be accomplished on or about that date pending final approvals.
Dunkin Brands Group, Inc., together with its auxiliaries, develops, franchises, and licenses quick service restaurants under the Dunkin Donuts and Baskin-Robbins brands worldwide. The company operates through four segments: Dunkin’ Donuts U.S., Dunkin’ Donuts International, Baskin-Robbins U.S., and Baskin-Robbins International.
Finally, Momenta Pharmaceuticals Inc. (NASDAQ:MNTA), ended its last trade with 7.89% gain, and closed at $20.09.
Momenta Pharmaceuticals, presented new data from studies conducted as part of the ANDA submission for once daily Glatopa (glatiramer acetate injection) at the 67th American Academy of Neurology (AAN) Annual Meeting in Washington D.C. The posters presented provide examples of a selection of methods the Company utilized to show the equivalence of Glatopa and once daily COPAXONE 20 mg.
Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for oncology and autoimmune diseases.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
